New York, March 26, 2015 -- Moody's Investors Service put Baxter International, Inc.'s long-term A3 and short-term Prime-2 ratings on review for downgrade as the company gets closer to the July 1, 2015 date anticipated for the separation of its bioscience business into a new publicly traded company to be named Baxalta. The ratings are on review for downgrade based on Moody's belief that post-separation, Baxter's smaller, less diverse, and lower margin business could result in a credit profile that is no longer sufficient to maintain its A3 rating.

Vollständigen Artikel bei Moodys lesen